Acrivon Therapeutics Inc. (ACRV) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ACRV scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine (7 / 20): Per the RQD rating, ROIC is -35% and FCF yield is 0%. For a prospective investor, this pillar signals that the business is not currently generating returns on invested capital or free cash flow, so value must rest on future outcomes rather than present earnings power.
• Whale 13F Flow (6 / 20): The RQD rating references institutional accumulation and options positioning, but the holders section contains no 13F detail in the source data. The low score suggests limited evidence of supportive institutional demand.
• Insider Conviction (5 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow is weak. Insider activity in the news wire is limited to an automatic tax-withholding sale, which is not a conviction signal.
• Macro Regime Fit (10 / 20): Per the RQD rating, beta is 1.0 and sector sensitivity is noted. Beta of 1.0 means the stock is expected to move in line with the broader market; the score reflects the absence of a clear macro tailwind in the data provided.
• Forensic Balance Sheet (10 / 20): Per the RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. These readings sit in a mixed zone: the Z-score is not in distress territory on its face, but the low Piotroski score points to weak fundamental health signals.

Taken together, the rating frames ACRV as a speculative, pre-revenue setting where the upside case depends on clinical and pipeline progress rather than current cash generation. The main valuation tradeoff is that a $75.4M market capitalization against sustained operating losses leaves little margin for execution error. Upside drivers would be pipeline milestones reaching the market; the downside is continued cash burn and dilution risk, which the source data does not quantify.

Acrivon Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Per the Yahoo Finance and Stock Titan news items, the company is advancing a pipeline that includes ACR-7280, an oral CDK11 inhibitor targeting an IND filing in the first half of 2027, and ACR-2316, a WEE1/PKMYT1 inhibitor with early Phase 1/2 results. Per the SEC financials, reported revenue is $0.0M across the periods shown, so the source data does not indicate a commercial product revenue stream. Customer and monetization details are not available in source data.

Per the SEC financials, the company reported operating losses in each period shown, with net margin at 0% per the market data reflecting absent revenue. Per the Roarable RQD rating, ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9 per the RQD forensic pillar, with Debt/Equity at 0.5. Reported cash of $41.5M at FY 2025 compares with FCF of $-65.3M in the same year, indicating the cash balance covers less than a full year of reported cash burn at that rate.

• Pipeline advancement: Per the Yahoo Finance report, ACR-7280 is advancing toward an IND filing in the first half of 2027.
• Clinical presentation: Per the Yahoo Finance report, a late-breaking oral plenary presentation of early Phase 1/2 results for ACR-2316 is scheduled at the 38th EORTC-NCI-AACR Symposium.
• Preclinical signal: Per the Stock Titan report, a drug candidate produced complete tumor regression in mouse leukemia models.
• Insider activity: Per the Stock Titan report, an automatic tax-withholding sale covered 513 shares.
• Price action: Per the Stock Titan micro-cap report, the stock ticked up 1.08% to $1.88 in a separate session, while the market data shows the current price at $1.66 with a change of -5.68%.

Risk watch items: early-stage clinical data is preliminary; the market data shows the stock 47% below its 52-week high of $3.56 (computed from source figures). Butterfly Supply-Chain Graph: Not available in source data — the graph reports no supply chain and no butterfly links or proprietary signals.

• What is the company's cash runway at the current quarterly burn rate, and does the $41.5M FY 2025 cash balance fund operations through the IND timeline?
• What is the debt structure behind the reported Debt/Equity of 0.5, given that debt is shown as N/A in each period?
• What share count and dilution exposure exist, since EPS is N/A across periods?
• Who are the institutional and insider holders, given that the holders dataset is empty?
• How durable are the early Phase 1/2 results for ACR-2316 once full data is reviewed?